My watch list  

3 Current news of Actelion

matching the following criteria

Actelion/Roche S1P1 alliance achieves clinical milestone

Dose-finding Phase IIb study started in patients with multiple sclerosis


Actelion Ltd announced that the selective S1P1 receptor agonist ACT-128800/ RG3477 has achieved an important clinical milestone. Actelion's first-in-class selective S1P1 (Sphingosine-1-phosphate) receptor agonist has entered into a Phase IIb dose-finding study in patients suffering from multiple ...


Tracleer (bosentan) receives EU approval for pediatric formulation

The first and only licensed pulmonary arterial hypertension therapy for children


Actelion Ltd announced that the pediatric dispersible formulation of Tracleer® (bosentan) for the treatment of pulmonary arterial hypertension (PAH) in children has been approved in the European Union. This approval makes Tracleer® the only PAH therapy with an approved pediatric formulation for ...


Actelion and Roche enter into autoimmune disorder collaboration


Actelion Ltd and Roche have announced today that they have entered into an exclusive worldwide collaboration to jointly develop and commercialize Actelion's selective S1P1 receptor agonist, an immunomodulator with the potential for once-a-day oral dosing. The compound is currently being developed ...


Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE